Fludeoxyglucose F18 Injection, USP is indicated for positron emission tomography (PET) imaging in the following settings:
Within the neurology setting, the recommended dose for pediatric patients is 2.6 mCi, as an intravenous injection. The optimal dose adjustment on the basis of body size or weight has not been determined [
see Use in Special Populations (8.4)
].
Available in 30 mL multiple-dose glass vials containing 0.74 to 11.1 GBq (20 to 300 mCi/mL) of Fludeoxyglucose F 18 Injection and 4.5 mg of sodium chloride in citrate buffer for intravenous administration.
None
Hypersensitivity reactions with pruritus, edema and rash have been reported in the post-marketing setting. Have emergency resuscitation equipment and personnel immediately available.
The interaction of Fludeoxyglucose F 18 Injection with other drugs taken by patients undergoing PET imaging has not been studied.
We receive information directly from the FDA and PrescriberPoint is updated as frequently as changes are made available